1185755-97-8

Basic information

• Product Name: C₁₄H₁₂BrFN₂O₃S
• Synonyms: C₁₄H₁₂BrFN₂O₃S
• CAS NO: 1185755-97-8
• Molecular Weight: 387.229
• Mol File: 1185755-97-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₁₄H₁₂BrFN₂O₃S(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₄H₁₂BrFN₂O₃S(1185755-97-8)
• EPA Substance Registry System: C₁₄H₁₂BrFN₂O₃S(1185755-97-8)

Safety Data

• Hazardous Substances Data: 1185755-97-8(Hazardous Substances Data)

Upstream product

• 1576-35-8 toluene-4-sulfonic acid hydrazide 
• 95383-36-1 2-bromo-4-fluorobenzoyl chloride 

Downstream Products

• 861418-50-0 {[chloro(2-bromo-4-fluorophenyl)methylene]hydrazide}-4-methylbenzene-sulfonic acid 

Relevant articles and documents

SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS

The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host diseases, T -cell mediated hypersensitivity diseases, contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism,Graves' Disease, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum sickness, uticaria, respiratory allergies, asthma, hayfever, allergic rhinitis, skin allergies, scleracielma, mycosis fungoides, acute inflammatory responses, acute respiratory distress syndrome, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II diabetes and cancers where PKC theta or other PKC-family kinases are activated, overexpressed or facilitate tumor growth or survival of tumor cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma, breast carcinoma and lung carcinoma or provides resistance to chemotherapeutic drugs.